Are antidepressants equally effective in the long-term treatment of major depressive disorder?

Massimiliano Buoli, Claudia Cumerlato Melter, Alice Caldiroli, A. Carlo Altamura

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: Few studies have compared simultaneously different antidepressants in long-term treatment of major depressive disorder (MDD). Long-term prevention of recurrences should be the main goal of MDD treatment. The purpose of this study was to compare antidepressants of different pharmacological classes in terms of retention in treatment (no discontinuation for recurrences, hospitalizations, side effects). Methods: One hundred and fifty outpatients with an MDD diagnosis, treated with antidepressants in mono-therapy, were included. Follow-up period was set at 24 months, and information have been obtained from charts, interviews with patients and their relatives, and from the Lombardy regional register. A survival analysis (Kaplan-Meier) was performed, considering recurrences, hospitalizations, or discontinuation due to side effects as 'death' events. Results: In our sample, 48.7% of the patients presented a recurrence within the first 2 years of treatment. Bupropion appears less effective in long-term treatment of MDD than the other compared antidepressants, with exception of fluoxetine (p = 0.09), amitriptyline (p = 0.13), fluvoxamine (p = 0.83), venlafaxine (p = 0.5), and trazodone (p = 0.58). Fluvoxamine appears to be less effective than citalopram (p = 0.036), paroxetine (p = 0.037), clomipramine (p = 0.05), sertraline (p = 0.011), and duloxetine (p = 0.024). Conclusions: Bupropion and fluvoxamine appear less effective in long-term treatment of MDD. These results should be confirmed by randomized placebo-controlled prospective studies with larger samples.

Original languageEnglish
Pages (from-to)21-27
Number of pages7
JournalHuman Psychopharmacology
Volume30
Issue number1
DOIs
Publication statusPublished - 2015

Fingerprint

Major Depressive Disorder
Antidepressive Agents
Fluvoxamine
Bupropion
Recurrence
Therapeutics
Hospitalization
Trazodone
Sertraline
Clomipramine
Paroxetine
Citalopram
Amitriptyline
Fluoxetine
Survival Analysis
Outpatients
Placebos
Prospective Studies
Pharmacology
Interviews

Keywords

  • Antidepressants
  • Maintenance treatment
  • Major depressive disorder (MDD)

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Neurology
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Are antidepressants equally effective in the long-term treatment of major depressive disorder? / Buoli, Massimiliano; Melter, Claudia Cumerlato; Caldiroli, Alice; Altamura, A. Carlo.

In: Human Psychopharmacology, Vol. 30, No. 1, 2015, p. 21-27.

Research output: Contribution to journalArticle

@article{67b5c26c2db64e5bac6cbc9995317044,
title = "Are antidepressants equally effective in the long-term treatment of major depressive disorder?",
abstract = "Objective: Few studies have compared simultaneously different antidepressants in long-term treatment of major depressive disorder (MDD). Long-term prevention of recurrences should be the main goal of MDD treatment. The purpose of this study was to compare antidepressants of different pharmacological classes in terms of retention in treatment (no discontinuation for recurrences, hospitalizations, side effects). Methods: One hundred and fifty outpatients with an MDD diagnosis, treated with antidepressants in mono-therapy, were included. Follow-up period was set at 24 months, and information have been obtained from charts, interviews with patients and their relatives, and from the Lombardy regional register. A survival analysis (Kaplan-Meier) was performed, considering recurrences, hospitalizations, or discontinuation due to side effects as 'death' events. Results: In our sample, 48.7{\%} of the patients presented a recurrence within the first 2 years of treatment. Bupropion appears less effective in long-term treatment of MDD than the other compared antidepressants, with exception of fluoxetine (p = 0.09), amitriptyline (p = 0.13), fluvoxamine (p = 0.83), venlafaxine (p = 0.5), and trazodone (p = 0.58). Fluvoxamine appears to be less effective than citalopram (p = 0.036), paroxetine (p = 0.037), clomipramine (p = 0.05), sertraline (p = 0.011), and duloxetine (p = 0.024). Conclusions: Bupropion and fluvoxamine appear less effective in long-term treatment of MDD. These results should be confirmed by randomized placebo-controlled prospective studies with larger samples.",
keywords = "Antidepressants, Maintenance treatment, Major depressive disorder (MDD)",
author = "Massimiliano Buoli and Melter, {Claudia Cumerlato} and Alice Caldiroli and Altamura, {A. Carlo}",
year = "2015",
doi = "10.1002/hup.2447",
language = "English",
volume = "30",
pages = "21--27",
journal = "Human Psychopharmacology",
issn = "0885-6222",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Are antidepressants equally effective in the long-term treatment of major depressive disorder?

AU - Buoli, Massimiliano

AU - Melter, Claudia Cumerlato

AU - Caldiroli, Alice

AU - Altamura, A. Carlo

PY - 2015

Y1 - 2015

N2 - Objective: Few studies have compared simultaneously different antidepressants in long-term treatment of major depressive disorder (MDD). Long-term prevention of recurrences should be the main goal of MDD treatment. The purpose of this study was to compare antidepressants of different pharmacological classes in terms of retention in treatment (no discontinuation for recurrences, hospitalizations, side effects). Methods: One hundred and fifty outpatients with an MDD diagnosis, treated with antidepressants in mono-therapy, were included. Follow-up period was set at 24 months, and information have been obtained from charts, interviews with patients and their relatives, and from the Lombardy regional register. A survival analysis (Kaplan-Meier) was performed, considering recurrences, hospitalizations, or discontinuation due to side effects as 'death' events. Results: In our sample, 48.7% of the patients presented a recurrence within the first 2 years of treatment. Bupropion appears less effective in long-term treatment of MDD than the other compared antidepressants, with exception of fluoxetine (p = 0.09), amitriptyline (p = 0.13), fluvoxamine (p = 0.83), venlafaxine (p = 0.5), and trazodone (p = 0.58). Fluvoxamine appears to be less effective than citalopram (p = 0.036), paroxetine (p = 0.037), clomipramine (p = 0.05), sertraline (p = 0.011), and duloxetine (p = 0.024). Conclusions: Bupropion and fluvoxamine appear less effective in long-term treatment of MDD. These results should be confirmed by randomized placebo-controlled prospective studies with larger samples.

AB - Objective: Few studies have compared simultaneously different antidepressants in long-term treatment of major depressive disorder (MDD). Long-term prevention of recurrences should be the main goal of MDD treatment. The purpose of this study was to compare antidepressants of different pharmacological classes in terms of retention in treatment (no discontinuation for recurrences, hospitalizations, side effects). Methods: One hundred and fifty outpatients with an MDD diagnosis, treated with antidepressants in mono-therapy, were included. Follow-up period was set at 24 months, and information have been obtained from charts, interviews with patients and their relatives, and from the Lombardy regional register. A survival analysis (Kaplan-Meier) was performed, considering recurrences, hospitalizations, or discontinuation due to side effects as 'death' events. Results: In our sample, 48.7% of the patients presented a recurrence within the first 2 years of treatment. Bupropion appears less effective in long-term treatment of MDD than the other compared antidepressants, with exception of fluoxetine (p = 0.09), amitriptyline (p = 0.13), fluvoxamine (p = 0.83), venlafaxine (p = 0.5), and trazodone (p = 0.58). Fluvoxamine appears to be less effective than citalopram (p = 0.036), paroxetine (p = 0.037), clomipramine (p = 0.05), sertraline (p = 0.011), and duloxetine (p = 0.024). Conclusions: Bupropion and fluvoxamine appear less effective in long-term treatment of MDD. These results should be confirmed by randomized placebo-controlled prospective studies with larger samples.

KW - Antidepressants

KW - Maintenance treatment

KW - Major depressive disorder (MDD)

UR - http://www.scopus.com/inward/record.url?scp=84920733599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920733599&partnerID=8YFLogxK

U2 - 10.1002/hup.2447

DO - 10.1002/hup.2447

M3 - Article

C2 - 25393889

AN - SCOPUS:84920733599

VL - 30

SP - 21

EP - 27

JO - Human Psychopharmacology

JF - Human Psychopharmacology

SN - 0885-6222

IS - 1

ER -